Deal Coming Soon????Finally do a catch up and listened to Q1 conf call and some awesome points of interest: 1.Ttheir aggressiveness with Business Development - recent appointment of VP and 15 potential products in pipeline 2. Mention of appointment of SL for European Operations - completed - Frank Rotmann 3. Strong likelihood to complete a deal in Q2 - Salagen and Estraderm from Novartis both combined 2014 sales of 10M, with territory expansion will be greater for MSL. 4. Really EXCITING is the potential for a transformational deal, bigger than Sintrom deal....2013 net sales of 28M 5. Fishman building a winner here, could actually grow revenue and EBITA by 100% YOY. Their EBITA target of >100M in 5 years will dust after 2 years. My prediction is SP of $5 by end this fiscal and with continued aggressive growth SP of $10 by end of 2016.